Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 691 to 705 of 1215 results for pain

  1. Optowire for measuring fractional flow reserve (MIB199)

    NICE has developed a medtech innovation briefing (MIB) on Optowire for measuring fractional flow reserve .

  2. Placement of pectus bar for pectus excavatum (also known as MIRPE or the Nuss procedure) (HTG199)

    Evidence-based recommendations on placement of pectus bar for pectus excavatum (Nuss procedure). This involves placing one or two steel (pectus) bars under the breastbone with the aim of raising it and correcting the abnormal shape.

  3. Percutaneous radiofrequency ablation for primary or secondary lung cancers (HTG244)

    Evidence-based recommendations on percutaneous radiofrequency ablation for primary or secondary lung cancers. This involves inserting 1 or more electrodes (needle-like probes) through the chest into the lung and using an electrical current to produce heat to destroy the cancer cells.

  4. Obinutuzumab in combination with chlorambucil for untreated chronic lymphocytic leukaemia (TA343)

    Evidence-based recommendations on obinutuzumab (Gazyvaro) with chlorambucil for untreated chronic lymphocytic leukaemia in adults.

  5. Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia (TA425)

    Evidence-based recommendations on dasatinib (Sprycel), nilotinib (Tasigna) and high-dose imatinib (Glivec) for treating imatinib-resistant or intolerant chronic myeloid leukaemia in adults.

  6. Autologous chondrocyte implantation for treating symptomatic articular cartilage defects of the knee (TA477)

    Evidence-based recommendations on autologous chondrocyte implantation in people with symptomatic articular cartilage defects of the knee.

  7. MRI guided focussed ultrasound for chronic pain

    Discontinued Reference number: GID-IP1043

  8. Radiofrequency denervation for osteoarthritic knee pain (IPG767)

    We have moved interventional procedures guidance 767 to become HealthTech guidance 686. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

  9. Lymphovenous anastomosis during axillary or inguinal node dissection for preventing secondary lymphoedema (HTG717)

    Evidence-based recommendations on lymphovenous anastomosis during axillary or inguinal node dissection for preventing secondary lymphoedema in adults. This involves diverting some of the lymphatic vessels around where lymph nodes have been removed to nearby veins.

  10. Biodegradable spacer insertion to reduce rectal toxicity during radiotherapy for prostate cancer (HTG659)

    Evidence-based recommendations on biodegradable spacer insertion to reduce rectal toxicity during radiotherapy for prostate cancer. This involves pushing the rectum slightly away from the prostate by inserting a balloon or injecting a gel (spacer) between them.

  11. Phrenic nerve transfer in brachial plexus injury (HTG322)

    Evidence-based recommendations on phrenic nerve transfer in brachial plexus injury. This involves finding the phrenic nerve, cutting it and joining it to the damaged nerve in the brachial plexus.

  12. Hand allotransplantation (HTG254)

    Evidence-based recommendations on hand transplant surgery (allotransplantation). This involves transplanting a hand from a recently deceased donor onto the amputated stump.

  13. Combined endoscopic and laparoscopic removal of colonic polyps (HTG354)

    Evidence-based recommendations on combined endoscopic and laparoscopic removal of colonic polyps. This involves using an endoscope in the bowel plus keyhole surgery through the skin of the abdomen to remove colonic polyps.

  14. Maximal cytoreductive surgery for advanced ovarian cancer (HTG668)

    Evidence-based recommendations on maximal cytoreductive surgery for advanced ovarian cancer. This involves removing all or almost all visible cancerous tissue. More tissue is removed than with standard surgery. The aim is to improve outcomes for people with advanced ovarian cancer.